

References

I-183

1. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with *RPE65*-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2017;390:849-60.
2. Dias MF, Joo K, Kemp JA, et al. Progress in Retinal and Eye Research (2017), <https://doi.org/10.1016/j.preteyeres.2017.10.004>.
3. Hayes, Inc. Hayes Health Technology Brief. *Luxturna (Voretigene neparvovec-rzyl)*. Lansdale, PA: Hayes, Inc.; December, 2017.
4. Weleber RG, Pennesi ME, Wilson DJ, et al. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood Onset Retinal Dystrophy. *AAO*. 2016;123:1606-1620.
5. Spark Therapeutics. Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2. *ClinicalTrials.gov*, U.S. National Library of Medicine, 24 Sept. 2010, Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2.
6. MICROMEDEX®SOLUTIONS Compendia. 2018. Voretigene Neparvovec-rzyl.
7. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Voretigene Neparvovec-rzyl.